Takeda’s investigational oral TYK2 inhibitor is supported by phase 3 LATITUDE data demonstrating significant skin clearance versus placebo and apremilast.
|Slideshows|September 12, 2018
Some psoriasis studies you shouldn't miss
Author(s)Dermatology Times Staff
Listen
0:00 / 0:00
In this slideshow, we highlight some of this year's clinical advances in psoriasis and plaque psoriasis.
Advertisement
In this slideshow, we highlight some of this year's clinical advances in psoriasis and plaque psoriasis.
Advertisement
Related to this article
In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.
Post hoc RESOLVE analysis shows that patients weighing at least 100 kg experience slower clinical response rates to brodalumab than those under 100 kg, establishing body weight over BMI as a key predictor of treatment timing.
Advertisement
Advertisement
Trending on Dermatology Times
1
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
2
Two-Year POETYK PsA-2 Data Show Durable Deucravacitinib Responses in Psoriatic Arthritis
3
Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study
4
Sun Protection in Beauty Routines: Is SPF Makeup Enough?
5